B-cell small lymphocytic lymphoma recurrent

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
BTK inhibitor 1 substance
BCL-2 inhibitor 1 substance
Unknown / small molecule 1 substance
Phase II: 2 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

2 trials
  • AstraZeneca AB Commercial
    ACALABRUTINIB; VENETOCLAX
    2024-518858-17-00 6 countries 2026 n=63
    Recruiting
  • Nurix Therapeutics Inc. Commercial
    NX-5948
    2025-521088-10-00 4 countries 2025 n=41 Orphan
    Recruiting

Phase I

1 trial
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ubix Therapeutics Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 1
Nurix Therapeutics Inc. Commercial 1 Phase II 1
New trials by year
2025
1
2026
1
← All indication landscapes